Immunologic specificity in glioblastoma: Antigen discovery and translational implications
Neuro-Oncology Advances · 09.09.2025 · 7 (Supplement_4) · iv41-iv70
DOI: 10.1093/noajnl/vdaf028 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology Advances, online erschienen am 09.09.2025. Verfasst von Cameron M Hill und 8 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 322 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Targeting Neoantigens in Glioblastoma, National Institute of Neurological Diseases and Stroke.
Abstract (Originalsprache)
Recent studies have highlighted the therapeutic potential of targeting tumor antigens (TAs) in glioblastoma (GBM). Several classes of TAs, such as tumor-associated, cancer testis, and tumor-specific antigens, have proven to be immunogenic and used safely in vaccines. Many of these vaccines have focused on tumor-associated or cancer testis antigens. However, tumor-specific antigens (TSA) present an ideal target due to the lack of tolerance and exclusive tumor expression, mitigating the risk of off-target effects. Most research on TSAs in GBM has aimed to uncover neoantigens, yet the dearth of shared neoantigens as well as the cost and labor-intensive process of identifying personal neoantigens have acted as barriers to treatment. A better understanding of the individual antigens spanning all three TA classes is important to improve the design of GBM antigen therapies and understand, fundamentally, the nature of immunologic specificity in glioma. We review the antigen classes in all cancers and how TAs are discovered. Then, we focus on the unique properties of GBM and the antigens that have been identified and used for therapy in GBM. Finally, we discuss translational considerations for future antigen-targeted treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts, USA.
- Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
- Biological and Biomedical Sciences Graduate Program, Harvard University, Cambridge, Massachusetts, USA.
ORCID-Profile: Gavin P Dunn
Förderung
- Targeting Neoantigens in Glioblastoma
- National Institute of Neurological Diseases and Stroke
Zitieren
APA
Hill, C. M., Wang, A. Z., Hsueh, B., Ramirez, R., Sherpa, N., Costa, M., Williams, O., Li, M., & Dunn, G. P. (2025). Immunologic specificity in glioblastoma: Antigen discovery and translational implications. Neuro-Oncology Advances, 7(Supplement_4), iv41-iv70. https://doi.org/10.1093/noajnl/vdaf028
Vancouver
Hill CM, Wang AZ, Hsueh B, Ramirez R, Sherpa N, Costa M, et al. Immunologic specificity in glioblastoma: Antigen discovery and translational implications. Neuro-Oncology Advances. 2025;7(Supplement_4):iv41-iv70. doi:10.1093/noajnl/vdaf028
BibTeX
@article{Hill2025,
author = {Hill, Cameron M and Wang, Anthony Z and Hsueh, Brian and Ramirez, Ramiro and Sherpa, Ngima and Costa, Marcelo and Williams, Ofir and Li, Mao and Dunn, Gavin P},
title = {Immunologic specificity in glioblastoma: Antigen discovery and translational implications},
journal = {Neuro-Oncology Advances},
year = {2025},
volume = {7},
number = {Supplement_4},
pages = {iv41--iv70},
doi = {10.1093/noajnl/vdaf028}
}
EUVIMED